ERBB2 and lung cancer: (25) reported a 71-year-old female smoker with stage 4 EGFR-mutant lung cancer with a previous diagnosis of atrial fibrillation and hypertension, with a left ventricular ejection fraction of 60% on baseline echocardiography, 40% left ventricular ejection fraction, diastolic dysfunction, left ventricular dilation, and pericardial effusion on echocardiography 1 month after treatment with afratinib, and normal left ventricular ejection fraction (60%) 1 week after discontinuation of afatinib, thus presumed that cardiac dysfunction was related to HER-2 inhibition.